Background: In chronic renal failure (CRF), evaluating treatment efficacy and predicting prognosis is crucial. High Mobility Group Protein B1 (HMGB1) and Nod-like Receptor Protein 3 (NLRP3) were chosen as key markers in chronic renal failure to elucidate their roles in treatment response and prognosis, offering potential insights for enhancing patient care strategies.
Objective: This study aims to analyze the clinical impact of HMGB1 and NLRP3 in patients with CRF undergoing hemodialysis. We investigated the relationship between HMGB1 and NLRP3 levels, the efficacy of hemodialysis treatment, and the prognosis for one-year survival.
Methods: An observational study was conducted. The study included 62 CRF patients (Group A) admitted to our hospital from May 2020 to August 2022, and 40 healthy individuals undergoing routine medical check-ups during the same period (Group B). We compared the levels of HMGB1 and NLRP3 in the peripheral blood of Group A and Group B. Furthermore, we assessed changes in HMGB1 and NLRP3 before and after hemodialysis in CRF patients to evaluate treatment efficacy and prognostic indicators for one-year survival.
Results: Group A exhibited significantly lower HMGB1 expression and higher NLRP3 expression compared to Group B. ROC curve analysis demonstrated that the areas under the curve (AUCs) for HMGB1 and NLRP3 in predicting effective hemodialysis for CRF were 0.884 (95% CI: 0.800-0.968) and 0.721 (95% CI: 0.594-0.848), respectively. The AUCs for HMGB1 and NLRP3 in predicting death from CRF were 0.885 (95% CI: 0.804-0.967) and 0.935 (95% CI: 0.875-0.995), respectively.
Conclusions: Both HMGB1 and NLRP3 levels serve as valuable indicators for assessing the efficacy and prognosis of CRF patients undergoing hemodialysis.